Profile data is unavailable for this security.
About the company
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.
- Revenue in USD (TTM)0.00
- Net income in USD-20.74m
- Incorporated1980
- Employees25.00
- LocationLisata Therapeutics Inc110 Allen Road, Second FloorBASKING RIDGE 07920United StatesUSA
- Phone+1 (908) 229-2590
- Fax+1 (845) 818-3588
- Websitehttps://www.lisata.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bolt Biotherapeutics Inc | 9.78m | -65.09m | 22.14m | 100.00 | -- | 0.3074 | -- | 2.26 | -1.71 | -1.71 | 0.2567 | 1.88 | 0.0687 | -- | -- | 97,790.00 | -45.72 | -48.32 | -52.52 | -54.03 | -- | -- | -665.56 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Pieris Pharmaceuticals Inc | 1.35m | -15.95m | 22.15m | 46.00 | -- | 1.36 | -- | 16.38 | -12.61 | -12.61 | 1.06 | 12.32 | 0.0338 | -- | 1.91 | 29,391.30 | -39.93 | -28.41 | -68.21 | -39.69 | -- | -- | -1,179.96 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Pulmatrix Inc | 10.01m | -9.66m | 22.35m | 22.00 | -- | 2.05 | -- | 2.23 | -2.64 | -2.64 | 2.74 | 2.99 | 0.4145 | -- | 23.16 | 454,772.70 | -40.00 | -46.91 | -44.64 | -58.12 | -- | -- | -96.51 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Cocrystal Pharma Inc | 0.00 | -18.70m | 22.38m | 12.00 | -- | 1.76 | -- | -- | -1.84 | -1.84 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -76.57 | -50.94 | -83.17 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.83m | 17.00 | -- | 2.10 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Forte Biosciences Inc | 0.00 | -34.20m | 23.36m | 11.00 | -- | 2.49 | -- | -- | -20.00 | -20.00 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -103.90 | -72.06 | -137.40 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Lisata Therapeutics Inc | 0.00 | -20.74m | 23.96m | 25.00 | -- | 0.7112 | -- | -- | -2.51 | -2.51 | 0.00 | 4.05 | 0.00 | -- | -- | 0.00 | -43.08 | -45.97 | -47.69 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Ibio Inc | 175.00k | -14.36m | 24.12m | 16.00 | -- | 1.28 | -- | 137.85 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Athira Pharma Inc | 0.00 | -109.22m | 24.68m | 65.00 | -- | 0.4311 | -- | -- | -2.85 | -2.85 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -80.62 | -30.73 | -101.80 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -7.61m | 24.86m | 4.00 | -- | 5.42 | -- | -- | -7.05 | -7.05 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -108.76 | -- | -125.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.57m | 24.88m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 24.95m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| ABPRO Holdings Inc | 0.00 | 4.29m | 24.97m | -- | 22.25 | 1.58 | -- | -- | 0.1396 | 0.1396 | 0.00 | 1.97 | 0.00 | -- | -- | -- | 2.48 | -- | 2.53 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 49,648.60 | -- | -- | -- |
| Equillium Inc | 45.91m | -4.62m | 25.19m | 45.00 | -- | 1.09 | -- | 0.5486 | -0.1316 | -0.1316 | 1.29 | 0.6543 | 1.02 | -- | 10.46 | 1,043,500.00 | -10.29 | -46.81 | -18.30 | -57.36 | -- | -- | -10.05 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 25.85m | 22.00 | -- | 0.2822 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Hookipa Pharma Inc | 50.00m | -43.37m | 25.92m | 151.00 | -- | 0.361 | -- | 0.5184 | -4.11 | -4.11 | 4.24 | 5.96 | 0.3653 | -- | 100.10 | 331,119.20 | -31.69 | -41.63 | -42.40 | -50.26 | -- | -- | -86.74 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
Data as of Nov 22 2024. Currency figures normalised to Lisata Therapeutics Inc's reporting currency: US Dollar USD
9.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 30 Sep 2024 | 284.67k | 3.42% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 185.33k | 2.23% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 103.62k | 1.25% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 56.01k | 0.67% |
| Geode Capital Management LLCas of 30 Sep 2024 | 55.68k | 0.67% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 17.34k | 0.21% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 14.35k | 0.17% |
| Cook Wealth LLCas of 30 Sep 2024 | 12.18k | 0.15% |
| G1 Execution Services LLCas of 30 Sep 2024 | 11.02k | 0.13% |
| Hightower Advisors LLCas of 30 Sep 2024 | 10.04k | 0.12% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
